Andrew R Gorringe

Summary

Affiliation: Health Protection Agency
Country: UK

Publications

  1. ncbi The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Andrew Gorringe
    Health Protection Agency, Porton Down, Salisbury SP4 0JG, UK
    Vaccine 23:2210-3. 2005
  2. ncbi Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease?
    Andrew R Gorringe
    Centre for Emergency Preparedness and Response, Health Protection Agency, Porton Down, Salisbury, SP4 0JG, UK
    Expert Rev Vaccines 4:373-9. 2005
  3. ncbi Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Michelle Finney
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK
    Hum Vaccin 4:23-30. 2008
  4. ncbi Bexsero: a multicomponent vaccine for prevention of meningococcal disease
    Andrew R Gorringe
    Health Protection Agency, Porton Down, Salisbury UK
    Hum Vaccin Immunother 8:174-83. 2012
  5. ncbi 16th International Pathogenic Neisseria Conference: recent progress towards effective meningococcal disease vaccines
    Andrew R Gorringe
    Health Protection Agency, Center for Emergency Preparedness and Responses, Porton Down, Salisbury, UK
    Hum Vaccin 5:53-6. 2009
  6. ncbi From pertussis to meningococcal disease and back
    Andrew Gorringe
    Health Protection Agency, Porton Down, Salisbury UK
    Hum Vaccin 7:398-401. 2011
  7. ncbi Experimental disease models for the assessment of meningococcal vaccines
    A R Gorringe
    Health Protection Agency, Porton Down, Salisbury SP40JG, UK
    Vaccine 23:2214-7. 2005
  8. ncbi Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Andrew R Gorringe
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK
    Clin Vaccine Immunol 16:1113-20. 2009
  9. ncbi Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens
    Thomas E Vaughan
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury SP4 0JG, UK
    Vaccine 24:5277-93. 2006
  10. ncbi Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
    Infect Immun 74:4557-65. 2006

Collaborators

Detail Information

Publications16

  1. ncbi The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Andrew Gorringe
    Health Protection Agency, Porton Down, Salisbury SP4 0JG, UK
    Vaccine 23:2210-3. 2005
    ..The vaccine is currently being manufactured and validated ELISA protocols have been developed for the analysis of serological responses...
  2. ncbi Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease?
    Andrew R Gorringe
    Centre for Emergency Preparedness and Response, Health Protection Agency, Porton Down, Salisbury, SP4 0JG, UK
    Expert Rev Vaccines 4:373-9. 2005
    ..lactamica-based vaccines can protect in experimental models of meningococcal disease. The potential for these vaccines to be effective in preventing meningococcal disease is discussed...
  3. ncbi Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Michelle Finney
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK
    Hum Vaccin 4:23-30. 2008
    ..However, such antisera did mediate opsonophagocytosis, suggestingthat this may did mediate opsonophagocytosis, suggesting that this may be a mechanism by which this vaccine protects in a mouse model of meningococcal bacteraemia...
  4. ncbi Bexsero: a multicomponent vaccine for prevention of meningococcal disease
    Andrew R Gorringe
    Health Protection Agency, Porton Down, Salisbury UK
    Hum Vaccin Immunother 8:174-83. 2012
    ....
  5. ncbi 16th International Pathogenic Neisseria Conference: recent progress towards effective meningococcal disease vaccines
    Andrew R Gorringe
    Health Protection Agency, Center for Emergency Preparedness and Responses, Porton Down, Salisbury, UK
    Hum Vaccin 5:53-6. 2009
    ..Promising results from both vaccines with genetically-detoxified lipooligosaccharide and overexpressed heterologous antigens, OMV's from Neisseria lactamica and recombinant Opa proteins...
  6. ncbi From pertussis to meningococcal disease and back
    Andrew Gorringe
    Health Protection Agency, Porton Down, Salisbury UK
    Hum Vaccin 7:398-401. 2011
    ..The resurgence of pertussis seen in some countries alerted me to the lack of understanding of protective immune responses to Bordetella pertussis infection and disease and this is now an active area of research...
  7. ncbi Experimental disease models for the assessment of meningococcal vaccines
    A R Gorringe
    Health Protection Agency, Porton Down, Salisbury SP40JG, UK
    Vaccine 23:2214-7. 2005
    ..However, the duration of bacteraemia is short, mortality is low and active protection cannot be assessed. Recent developments using transgenic mice expressing human CD46 give hope that improved models will be developed...
  8. ncbi Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Andrew R Gorringe
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK
    Clin Vaccine Immunol 16:1113-20. 2009
    ..In conclusion, this N. lactamica OMV vaccine is safe and induces a weak but broad humoral immune response to N. meningitidis...
  9. ncbi Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens
    Thomas E Vaughan
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury SP4 0JG, UK
    Vaccine 24:5277-93. 2006
    ..meningitidis MC58 genome. The results suggest that OMVs have a hitherto unappreciated complexity and pinpoint novel candidate antigens for further characterisation...
  10. ncbi Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
    Infect Immun 74:4557-65. 2006
    ..These results emphasize the need for standardized methodologies that would allow a more robust comparison of assays between laboratories and promote their further evaluation as correlates of protection against MenB disease...
  11. ncbi Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease
    Frances Alexander
    Health Protection Agency, Porton Down, Salisbury, United Kingdom
    Clin Vaccine Immunol 19:1776-83. 2012
    ..However, a surprising number of individuals had moderate Fim2 IgG concentrations despite very few isolates of that serotype obtained in the sampling period...
  12. ncbi Neisserial outer membrane vesicles bind the coinhibitory receptor carcinoembryonic antigen-related cellular adhesion molecule 1 and suppress CD4+ T lymphocyte function
    Hannah S W Lee
    Department of Medical Genetics and Microbiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada
    Infect Immun 75:4449-55. 2007
    ..Moreover, it demonstrates that OMV-based vaccines must be developed from strains that lack CEACAM1-binding Opa variants...
  13. ncbi Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential
    Karen Reddin
    Molecular Infectious Diseases Group, Department of Paediatrics, Faculty of Medicine, Imperial College London, UK
    Infect Immun 72:6511-8. 2004
    ....
  14. ncbi Neisseria lactamica protects against experimental meningococcal infection
    Kerry J Oliver
    Centre for Applied Microbiology and Research, Salisbury SP4 0JG, United Kingdom
    Infect Immun 70:3621-6. 2002
    ..The results confirm the potential of N. lactamica to form the basis of a vaccine against meningococcal disease...
  15. ncbi Homology modelling of transferrin-binding protein A from Neisseria meningitidis
    Jonathan S Oakhill
    Metalloprotein Research Group, Randall Division of Cell and Molecular Biophysics, King s College London, New Hunt s House, Guy s Campus, London SE1 1UL, UK
    Protein Eng Des Sel 18:221-8. 2005
    ..The relevance of this channel and the spatial arrangement of external loops, to the mechanism of iron translocation employed by TbpA is discussed...
  16. ncbi Expression and purification of functional recombinant meningococcal transferrin-binding protein A
    Jonathan S Oakhill
    Metalloprotein Research Group, The Randall Centre for Molecular Mechanisms of Cell Function, King s College London, London SE1 1UL, UK
    Biochem J 364:613-6. 2002
    ..In the present study we have optimized a procedure for obtaining purified, functionally active recombinant TbpA at a level and stability necessary for the initiation of such studies...